Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma-Reference-Cited by-同舟云学术

Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma

Published:2017-03-15 Issue:6 Volume:31 Page:1463-1466
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Einsele H,Knop S,Vogel M,Müller J,Kropff M,Metzner B,Langer C,Sayer H,Jung W,Dürk H A,Salwender H,Wandt H,Bassermann F,Gramatzki M,Rösler W,Wolf H-H,Brugger W,Engelhardt M,Fischer T,Liebisch P,Straka C

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/leu201783.pdf

Reference11 articles.

1. Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, Garcia SR, Powles R et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia 2014; 28: 981–992.

2. Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012; 120: 9–19.

3. Leleu X, Fouquet G, Hebraud B, Roussel M, Caillot D, Chretien ML et al. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma. Leukemia 2013; 27: 2242–2244.

4. Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood 2013; 121: 4647–4654.

5. Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database;Blood Cancer Journal;2023-09-05

2. Nonselective proteasome inhibitors in multiple myeloma and future perspectives;Expert Opinion on Pharmacotherapy;2021-12-10

3. Full or intensity‐reduced high‐dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma;European Journal of Haematology;2021-08-28

4. Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline;British Journal of Haematology;2021-03-21

5. The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review;Annals of Hematology;2020-10-29